4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program

by Business Wire • 2026/04/14 • 0 Comments

NEWTON, Mass.--(BUSINESS WIRE)-- #4DPath--4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program

← ASCRS 2026

Atia Vision Announces Durable 36-Month Results from First-in-Human Study of their Dynamic Shape-Changing OmniVu Intraocular Lens System →

Post navigation